Items tagged with Drug-resistant TB
Scaling up multidrug-resistant tuberculosis care in China (post)
Drug-resistant tuberculosis threatens to undermine advances in tuberculosis control worldwide. Multidrug-resistant tuberculosis (MDRTB), defined as resistance to isoniazid and rifampicin, requires treatment for up to 24 months with expensive diagnostics and second-line drugs. Fewer than 15% of patients diagnosed with tuberculosis worldwide receive drug susceptibility testing (DST); only 20% of the estimated 480 000 new cases of MDRTB annually are treated appropriately.1 Of these, cure rarely exceeds 65%. Those on ineffective therapy risk acquiring additional resistance and spreading drug-resistant tuberculosis to others. In recent years, new molecular diagnostics and antituberculosis drugs promise an opportunity to improve outcomes for patients with drug-resistant tuberculosis, leading the WHO to prioritise universal access to prevention, diagnosis, and treatment of MDRTB.1 However, identification of viable models for coordinating and financing scale-up of such services remains a major challenge for most middle-income and low-income countries.
Scientists use DNA sequencing to trace the spread of drug-resistant TB (post)
Scientists have for the first time used DNA sequencing to trace the fatal spread of multidrug-resistant tuberculosis between patients in the UK.
South Africa: More than 40,000 prisoners screened for MDR-TB (post)
More than 40,000 prisoners have been screened for multidrug-resistant tuberculosis (MDR-TB) this year as government attempts to tackle TB in correctional facilities.
Drug-resistant TB threatens to kill 75 million people by 2050, cost $16.7 trillion (post)
Over the next 35 years, multidrug-resistant tuberculosis will kill 75 million people and could cost the global economy a cumulative $16.7 trillion - the equivalent of the European Union’s annual output, a UK parliamentary group said on Tuesday.
Hear to help: Enabling early detection of hearing loss resulting from anti-tuberculosis treatment to improve the lives of our patients (post)
25 March 2015 - South Africa - South Africa has one of the highest levels of multidrug-resistant tuberculosis (MDR-TB) in the world, affecting 15,400 people in 2012 alone. Current standard of care for the disease involves the use of toxic medicines, which, among other side effects, can also cause hearing loss in about 30% of patients.
Case Western Reserve to lead international research on resistance to bacteria causing TB (post)
After discovering a unique group of people resistant to tuberculosis (TB) infection, Case Western Reserve researchers are leading an international team dedicated to understanding exactly how they fight off a disease that claims 1.5 million lives each year.
US to help China fight tough TB strain (post)
Chinese and US experts have pledged greater collaboration to eradicate a multidrug-resistant tuberculosis in China, while touting breakthroughs in the fight against the "silent disease".
Khayelitsha clinic leads the way for new TB drug (post)
Drug-resistant tuberculosis is a major health challenge across much of Africa, but a new medicine being pioneered in South Africa could be a breakthrough after decades of frustration.
Locally-sourced drugs effective as internationally quality assured drugs for treating multidrug-resistant TB (post)
Locally-sourced antibiotics can be as effective as ‘internationally quality-assured’ (IQA) antibiotics for treating multidrug-resistant tuberculosis (MDR-TB) in Pakistan, and may help avoid delays in starting treatment while programmes wait for drugs to arrive from overseas, according to new research published in PLOS ONE.
Page 14 of 117 · Total posts: 0
←First 13 14 15 Last→